HK1028545A1 - Therapeutic formulations containing snake and/or insect venom for the prophylaxis and therapy of neoplasms - Google Patents

Therapeutic formulations containing snake and/or insect venom for the prophylaxis and therapy of neoplasms

Info

Publication number
HK1028545A1
HK1028545A1 HK00106741.9A HK00106741A HK1028545A1 HK 1028545 A1 HK1028545 A1 HK 1028545A1 HK 00106741 A HK00106741 A HK 00106741A HK 1028545 A1 HK1028545 A1 HK 1028545A1
Authority
HK
Hong Kong
Prior art keywords
neoplasms
prophylaxis
therapy
formulations containing
therapeutic formulations
Prior art date
Application number
HK00106741.9A
Other languages
English (en)
Inventor
Elizabeth Shanahan-Prendergast
Original Assignee
Elizabeth Shanahan-Prendergast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elizabeth Shanahan-Prendergast filed Critical Elizabeth Shanahan-Prendergast
Publication of HK1028545A1 publication Critical patent/HK1028545A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A61K35/583—Snakes; Lizards, e.g. chameleons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01004—Phospholipase A2 (3.1.1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04011—Phosphoinositide phospholipase C (3.1.4.11)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
HK00106741.9A 1996-09-11 2000-10-23 Therapeutic formulations containing snake and/or insect venom for the prophylaxis and therapy of neoplasms HK1028545A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2517996P 1996-09-11 1996-09-11
PCT/IB1997/001091 WO1998010776A1 (fr) 1996-09-11 1997-09-10 Formulations therapeutiques contenant du venin ou un antiserum contre le venin, utilise seul ou combine pour la prophylaxie therapeutique et le traitement de neoplasmes

Publications (1)

Publication Number Publication Date
HK1028545A1 true HK1028545A1 (en) 2001-02-23

Family

ID=21824505

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00106741.9A HK1028545A1 (en) 1996-09-11 2000-10-23 Therapeutic formulations containing snake and/or insect venom for the prophylaxis and therapy of neoplasms

Country Status (10)

Country Link
US (5) US20030175277A1 (fr)
EP (1) EP1019068B1 (fr)
AT (1) ATE435023T1 (fr)
AU (1) AU741943B2 (fr)
CA (1) CA2265631A1 (fr)
DE (1) DE69739482D1 (fr)
ES (1) ES2329529T3 (fr)
HK (1) HK1028545A1 (fr)
PT (1) PT1019068E (fr)
WO (1) WO1998010776A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69934325T2 (de) * 1998-09-08 2007-07-05 Biomolecular Products, Inc., Byfield Zusammenstellungen zur erhöhung der darmabsoption von fetten
AU1534900A (en) * 1998-11-12 2000-06-05 Analytica Ltd A method of treatment
KR100831118B1 (ko) * 2000-05-26 2008-05-20 심포젠 에이/에스 알레르기를 치료하기 위한 재조합 폴리클로날 항체 또는정제된 폴리클로날 항체
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
MXPA03002934A (es) * 2000-10-10 2004-05-04 Univ North Carolina Composiciones y metodos para aumentar la permeabilidad paracelular a traves de las barreras epiteliales y endoteliales.
WO2002085391A1 (fr) * 2001-04-24 2002-10-31 Luis Alberto Costa Utilisation d'une phospholipase a2 pour la preparation de compositions pharmaceutiques et/ou cosmetiques pour la prevention et/ou le traitement local et/ou systemique de maladies et/ou de processus provoques par des pathogenes intra ou extra cellulaires exprimant des phospholipides de membrane
DE10330712A1 (de) * 2003-07-08 2005-01-27 Toximed Gmbh Pharmarzeutischer Wirkstoff gegen Kolonkarzinome und andere Tumorarten
DE10342747A1 (de) * 2003-09-16 2005-04-28 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Melanome

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189471A (en) 1978-07-11 1980-02-19 Merck & Co., Inc. Immunologic glycolipid adjuvants
EP0064366A1 (fr) 1981-04-29 1982-11-10 Beecham Group Plc Compositions pharmaceutiques
ES2054668T3 (es) * 1986-05-19 1994-08-16 Ventech Research Inc Composicion farmaceutica util para el tratamiento de carcinomas y otras enfermedades y un proceso para la preparacion del componente activo y de la composicion farmaceutica.
US5053492A (en) * 1986-08-07 1991-10-01 Board Of Regents, The University Of Texas System Immunopurification using monoclonal antibodies to Mojave toxin
US5164196A (en) * 1987-05-19 1992-11-17 Ventech Research, Inc. Crotoxin complex as cytotoxic agent
US5019508A (en) * 1987-08-27 1991-05-28 Biotechnology Research Partners, Ltd. Synovial phospholipases
US4822608A (en) * 1987-09-14 1989-04-18 Vespa Laboratories, Inc. Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom or proteinaceous or polypeptide components thereof
FR2623508B1 (fr) * 1987-11-20 1990-04-20 Commissariat Energie Atomique Proteine basique denommee phospholipase a2 isolee de venin de serpent de la famille des elapides et sa sequence en amino-acides, derives et fragments de ladite proteine, leur procede d'obtention, compositions therapeutiques et agents de diagnostic contenant ladite proteine et/ou ses derives et/ou ses fragments
US5622832A (en) * 1990-02-28 1997-04-22 Genetics Institute, Inc. Arachidonic acid releasing phospholipase A2 enzyme and methods of use
JP2984029B2 (ja) * 1990-05-30 1999-11-29 塩野義製薬株式会社 膜型ホスホリパーゼａ▲下２▼を認識するモノクローナル抗体および膜型ホスホリパーゼａ▲下２▼の免疫測定法
US5178864A (en) * 1990-08-14 1993-01-12 Mit Lipoprotein removal by soluble enzymes
DE4142552A1 (de) 1991-12-21 1993-06-24 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen die typ i phospholipase a(pfeil abwaerts)2(pfeil abwaerts) als entzuendungshemmendes therapeutikum
US5565431A (en) * 1994-06-20 1996-10-15 Lipps; Binie V. Cancer cell inhibitors and method
FR2722692B1 (fr) 1994-07-20 1997-03-21 Rhone Poulenc Rorer Sa Medicament a base de phospholipase a2 de venin d'abeille
US5698583A (en) * 1994-11-15 1997-12-16 Crescenti; Ernesto J.V. Oligoelements and phospholipase A2 immuno-enhancer compositions, preparation thereof, and use thereof

Also Published As

Publication number Publication date
PT1019068E (pt) 2009-10-08
EP1019068B1 (fr) 2009-07-01
EP1019068A1 (fr) 2000-07-19
DE69739482D1 (de) 2009-08-13
ATE435023T1 (de) 2009-07-15
ES2329529T3 (es) 2009-11-26
US8580744B2 (en) 2013-11-12
US20040131632A1 (en) 2004-07-08
US20080044431A1 (en) 2008-02-21
US20100196459A1 (en) 2010-08-05
WO1998010776A1 (fr) 1998-03-19
CA2265631A1 (fr) 1998-03-19
AU741943B2 (en) 2001-12-13
US20030175277A1 (en) 2003-09-18
AU4132397A (en) 1998-04-02
US20120258115A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
AU2431995A (en) Method for reduction of headache pain
AU549481B2 (en) Hair growing agent
MY119375A (en) Treatment of tinnitus using neuroprotective agents
IT1283102B1 (it) Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
UA41355C2 (uk) Засіб для лікування нейро-сніду
MX9401294A (es) Derivados de azolona sustituida
EP0746313A4 (fr) Procede de traitement de petits ulceres buccaux
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
HK1028545A1 (en) Therapeutic formulations containing snake and/or insect venom for the prophylaxis and therapy of neoplasms
DK0817646T3 (da) Fremgangsmåder til behandling af inflammation og præparater derfor
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
NO984446L (no) FremgangsmÕte for behandling av smerte
SE9601395D0 (sv) New therapeutic treatment 1
AU3474593A (en) Hypericin treatment of vaccine agents for improved immunogenicity
IL123001A0 (en) Analgesic from snake venom
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
IT1293583B1 (it) Uso dell'acido gammaidrossibutirrico per il trattamento delle sindromi demenziali
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
AU4261399A (en) Use of crataegus formulations for prophylaxis and treatment of neoplastic diseases
DK1140103T3 (da) Ponazuril til behandling af neurologiske og abortfremkaldende sygdomme forårsaget af Coccidia
ES2186153T3 (es) Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc.
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
ES2170377T3 (es) Composicion que contiene quitosana.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140910